Seeking Alpha

More on Teva (TEVA -2.1%) Q4: net profit -37% to $320M as revenue falls 7.5%. U.S. sales -14% to...

More on Teva (TEVA -2.1%) Q4: net profit -37% to $320M as revenue falls 7.5%. U.S. sales -14% to $2.6B amid a sharp fall in Provigil (sleep disorder) due to generic competition. Copaxone global revenues +14% to $1.1B, but faces increasing competition. Expects to launch 23 generic drugs in 2013, as in 2012. Reiterates 2013 revenue forecast of $19.5-20.5B and adjusted EPS of $4.85-5.15. Declares dividend of 1.15 shekels (31 cents) a share, +15% from Q3.
Comments (2)
  • doc47
    , contributor
    Comments (1015) | Send Message
     
    To all the rose-tinted glasses Teva fans that appear here regularly: Get well soon!
    7 Feb 2013, 09:50 AM Reply Like
  • Garthilk
    , contributor
    Comments (589) | Send Message
     
    Definately more significant downside in the future.
    7 Feb 2013, 10:39 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|